Found 79 articles for: "atopic Derm"
Use of an Eczema Moisturizer or Cream Provides Immediate, Sustained Itch Relief in Eczema-Prone Individuals
August 2026 | Volume 25 | Issue 8 | Original Article | 737 | Copyright © August 2026
Background: Eczema is a prevalent, chronic skin condition that affects up to 10% of adults globally and is characterized by recurrent eczematous lesions. Intense itch is often th...
Read MoreAtopic Dermatitis Flare Following Initiation of Nemolizumab
August 2026 | Volume 25 | Issue 8 | Case Reports | 751 | Copyright © August 2026
Background: Atopic dermatitis (AD) is a chronic inflammatory skin disorder marked by intense pruritus and episodic flares. While nemolizumab, an interleukin-31 (IL-31) inhibitor,...
Read MoreDual Therapy for Atopic Dermatitis: Lebrikizumab and JAK inhibitors used in Tandem for Treatment-Resistant Cases
June 2026 | Volume 25 | Issue 6 | Features | 569 | Copyright © June 2026
Racial and Ethnic Disparities in Access to Advanced Therapies for Atopic Dermatitis in the United States
January 2026 | Volume 25 | Issue 1 | Original Article | 54 | Copyright © January 2026
Background: Atopic dermatitis (AD) disproportionately affects diverse patient populations, and complex factors influence access to treatment among different racial and ethnic gro...
Read MoreReal-World Dupilumab Persistence in United States Children, Adolescents, and Adults With Atopic Dermatitis Over 24 Months
October 2025 | Volume 24 | Issue 10 | Original Article | 996 | Copyright © October 2025
Background: Dupilumab has demonstrated benefits in patients with atopic dermatitis (AD), but there is limited information on real-world rates of dupilumab persistence and supplem...
Read MoreSAIGE I: Staphylococcus aureus, Immunological, Genetic, and Environmental (SAIGE) Factors Contributing to Atopic Dermatitis and the Use of Ceramide-Containing Skincare
October 2025 | Volume 24 | Issue 10 | Original Article | 1012 | Copyright © October 2025
Background: Atopic dermatitis (AD) is a common heterogeneous disorder that typically starts in infancy and early childhood, is associated with the development of comorbidities, a...
Read MoreEvaluating Topical Nitric Oxide Formulations Against an Atopic Dermatitis Methicillin-Resistant S. Aureus Isolate in a Porcine Infection Model
October 2025 | Volume 24 | Issue 10 | Original Article | 1003 | Copyright © October 2025
Background: Atopic dermatitis (AD) is a skin disorder characterized by reduced skin barrier function, which often leads to recurring infections, predominantly by Staphylococcus a...
Read MoreIncreased Risk of Subcutaneous Nodules and Lipomas Following Influenza Vaccination: A Multicenter TriNetX Cohort Study
October 2025 | Volume 24 | Issue 10 | Original Article | 974 | Copyright © October 2025
Background: Influenza vaccination represents one of the most widespread public health interventions. Localized cutaneous reactions, including nodules and pruritus, may occur rare...
Read More1% Colloidal Oatmeal Cream/Baby Wash Regimen Improved Atopic Dermatitis in Pediatric Patients From First Use
October 2025 | Volume 24 | Issue 10 | Original Article | 979 | Copyright © October 2025
Background and Objective: Atopic dermatitis (AD) affects 15% to 20% of children. Evidence supporting the effectiveness of colloidal oatmeal-based moisturizers in improving mild-t...
Read MoreRuxolitinib Cream Versus Triamcinolone Cream in Adults With Mild to Moderate Atopic Dermatitis
October 2025 | Volume 24 | Issue 10 | Original Article | 1036 | Copyright © October 2025
Atopic dermatitis (AD), a chronic inflammatory skin disease, is typically treated with topical corticosteroids in patients with mild to moderate disease, creating an ongoing need for nonsteroidal...
Read MoreThe Role of Simultaneous Janus Kinase Inhibitor and Biologic Therapy Use for Refractory Atopic Dermatitis
October 2025 | Volume 24 | Issue 10 | Case Reports | 1043 | Copyright © October 2025
Beyond Inflammation and Itch: A Call for a Broader Framework in Atopic Dermatitis
October 2025 | Volume 24 | Issue 10 | Editorials | e62 | Copyright © October 2025
The Prevalence of Dupilumab-Associated Adverse Events Among Black and African American Adult Patients With Atopic Dermatitis: A Retrospective Chart Review
October 2025 | Volume 24 | Issue 10 | Features | 1054 | Copyright © October 2025
The Atopic Dermatitis Continuum: An Updated Paradigm for a Common Disorder and a Novel Multipurpose Treatment Option
September 2025 | Volume 24 | Issue 9 | Original Article | 920 | Copyright © September 2025
Background: Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disorder characterized by complex interactions among Staphylococcus aureus colonization and ...
Read MoreSAIGE II: The Role of Staphylococcus aureus in Skin Barrier Dysfunction and the Development and Severity of Atopic Dermatitis in Young Children
August 2025 | Volume 24 | Issue 8 | Original Article | 810 | Copyright © August 2025
Background: Atopic dermatitis (AD) is a chronic inflammatory skin condition that often manifests in infancy or early childhood, with significant impacts on quality of life and po...
Read MoreThe Prevalence of Dupilumab-Associated Adverse Events Among Black and African American Adult Patients With Atopic Dermatitis: A Retrospective Chart Review
August 2025 | Volume 24 | Issue 8 | Features | 8749 | Copyright © August 2025
Socioeconomic Disparities in Gentle Skin Care Access for Atopic Dermatitis: Affordability and Pharmacy Deserts
July 2025 | Volume 24 | Issue 7 | Original Article | 683 | Copyright © July 2025
Background: Gentle skin care is key to atopic dermatitis (AD) treatment, yet products are often expensive. Pharmacy deserts may exacerbate socioeconomic disparities in AD....
Read MorePractical Algorithm on Topical Treatment of Flaring Atopic Dermatitis (AD) With or Without Secondary Infection
June 2025 | Volume 24 | Issue 6 | Original Article | 621 | Copyright © June 2025
Acute exacerbations or flares are a key characteristic of atopic dermatitis (AD), often associated with sleep deprivation, as well as experiences of stigmatization, social withdrawal, anxiety, an...
Read MoreRapid Onset of Itch Relief With Tapinarof in Two Phase 3 Trials in Atopic Dermatitis
June 2025 | Volume 24 | Issue 6 | Original Article | 600 | Copyright © June 2025
Background: In the ADORING 1 and 2 phase 3 trials, tapinarof cream 1% once daily (QD) demonstrated significant efficacy and was well tolerated in adults and children down to 2 ye...
Read MorePDE4 Inhibitors: Bridging Molecular Insights With Clinical Impact
June 2025 | Volume 24 | Issue 6 | Original Article | 631 | Copyright © June 2025
© 2026 Journal of Drugs in Dermatology. All Rights Reserved. JDD, a peer-reviewed, MEDLINE®/PubMed® indexed journal, offers the dermatology community strong content of utmost quality and relevance on drugs, devices, and methods.
